Opiant receives $2.5 million milestone payment from Adapt
Opiant Pharmaceuticals Inc. announced this week that it has received $2.5 million from Adapt Pharma Ltd. as a milestone payment following Adapt’s first commercial sale of NARCAN Nasal Spray. Read More »